New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
Activate Your Account with an access code or Create a New Account
Gerlinde Wernig
Pathologist, Hematopathologist
Assistant Professor of Pathology at the Stanford University Medical Center
Practice Areas
- Pathology
Professional Education
- Board Certification: Anatomic Pathology, American Board of Pathology (2013)
- Board Certification: Hematology, American Board of Pathology (2013)
- Residency: Stanford Hospital and Clinics (2013) CA
- Fellowship: Stanford Hospital and Clinics (2012) CA
- Residency: Stanford Hospital and Clinics (2011) CA
- Fellowship: Friedrich-Wilhelms-University Bonn (2004) Germany
- Medical Education: Medical University of Vienna (1999) Austria
Publications
-
The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment
Wernig, G., Janzen, V., SCHAFER, R., Zweyer, M., Knauf, U., Hoegemeier, O., … Wernig, A. (2005). The vast majority of bone-marrow-derived cells integrated into mdx muscle fibers are silent despite long-term engraftment. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 102(33), 11852–11857. -
EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L
Wernig, G., Kharas, M. G., Mullally, A., Leeman, D. S., Okabe, R., George, T., … Gilliland, D. G. (2012). EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. LEUKEMIA, 26(4), 720–727. -
Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells
Kim, D., Wang, J., Willingham, S. B., Martin, R., Wernig, G., & Weissman, I. L. (2012). Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. LEUKEMIA, 26(12), 2538–2545. -
Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
Mullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., … Ebert, B. L. (2010). Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells. CANCER CELL, 17(6), 584–596.
-
Correction of CFTR malfunction and stimulation of Ca2+- activated Cl- channels restore HCO3- secretion in cystic fibrosis bile ductular cells
Zsembery, A., Jessner, W., Sitter, G., Spirli, C., Strazzabosco, M., & Graf, J. (2002). Correction of CFTR malfunction and stimulation of Ca2+- activated Cl- channels restore HCO3- secretion in cystic fibrosis bile ductular cells. HEPATOLOGY, 35(1), 95–104.
-
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., … Gilliland, D. G. (2005). Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. CANCER CELL, 7(4), 387–397.
-
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation
Lu, X. H., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., … Lodish, H. (2005). Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 102(52), 18962–18967.
-
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Wernig, G., Mercher, T., Okabe, R., Levine, R. L., Lee, B. H., & Gilliland, D. G. (2006). Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. BLOOD, 107(11), 4274–4281.
-
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model
Mercher, T., Wernig, G., Moore, S. A., Levine, R. L., Gu, T.-L., Frohling, S., … Gilliland, D. G. (2006). JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model. BLOOD, 108(8), 2770–2779.
-
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., … Levine, R. L. (2006). MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLOS MEDICINE, 3(7), 1140–1151.
-
Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
Levine, R. L., & Wernig, G. (2006). Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program, 233-?
-
The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes
Wernig, G., Gonneville, J. R. R., Crowley, B. J., Rodrigues, M. S., Reddy, M. M., Hudon, H. E., … Sattler, M. (2008). The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. BLOOD, 111(7), 3751–3759.
-
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia
Loriaux, M. M., Levine, R. L., Tyner, J. W., Froehling, S., Scholl, C., Stoffregen, E. P., … Druker, B. J. (2008). High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. BLOOD, 111(9), 4788–4796.
-
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera
Werning, G., Kharas, M. G., Okabe, R., Moore, S. A., Leeman, D. S., Cullen, D. E., … Gilliland, D. G. (2008). Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. CANCER CELL, 13(4), 311–320.
-
STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2
Tam, W. F., Haehnel, P. S., Schueler, A., Lee, B. H., Okabe, R., Zhu, N., … Kindler, T. (2013). STAT5 Is Crucial to Maintain Leukemic Stem Cells in Acute Myelogenous Leukemias Induced by MOZ-TIF2. CANCER RESEARCH, 73(1), 373–384.
-
Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands
Moraga, I., Wernig, G., Wilmes, S., Gryshkova, V., Richter, C. P., Hong, W.-J., … Garcia, K. C. (2015). Tuning Cytokine Receptor Signaling by Re-orienting Dimer Geometry with Surrogate Ligands. CELL, 160(6), 1196–1208.
